Association between increased serum interleukin-6 levels and sustained attention deficits in patients with major depressive disorder
暂无分享,去创建一个
Jeffrey K. Yao | Xin Yu | L. Hui | Jie Chen | G. Ye | G. Yin | Zhen Tang | J. Fu | S. Chen | Jia Li | T. Fu | Dong-wu Xu | J. Yao | Guangzhong Yin
[1] Y. Zang,et al. The Inter-Regional Connectivity Within the Default Mode Network During the Attentional Processes of Internal Focus and External Focus: An fMRI Study of Continuous Finger Force Feedback , 2019, Front. Psychol..
[2] J. Landowski,et al. Peripheral blood lymphocyte subpopulations in patients with bipolar disorder type II , 2019, Scientific Reports.
[3] Mohammad Fahim Kadir,et al. Evaluation of Serum Interleukin-6 and C-reactive Protein Levels in Drug-naïve Major Depressive Disorder Patients , 2019, Cureus.
[4] G. Lewis,et al. Childhood inflammatory markers and intelligence as predictors of subsequent persistent depressive symptoms: a longitudinal cohort study , 2017, Psychological Medicine.
[5] J. Wu,et al. Elevated triglyceride levels are associated with cognitive impairments among patients with major depressive disorder. , 2017, Comprehensive psychiatry.
[6] D. Goldsmith,et al. A meta-analysis of blood cytokine network alterations in psychiatric patients: comparisons between schizophrenia, bipolar disorder and depression , 2016, Molecular Psychiatry.
[7] Zhi-guo Wu,et al. Identification of IL6 as a susceptibility gene for major depressive disorder , 2016, Scientific Reports.
[8] F. Wright,et al. Gene expression in major depressive disorder. , 2016, Molecular psychiatry.
[9] F. Wright,et al. Gene expression in major depressive disorder , 2016, Molecular Psychiatry.
[10] R. Fonseca,et al. Executive function impairments in depression and bipolar disorder: association with functional impairment and quality of life. , 2016, Journal of affective disorders.
[11] W. Deng,et al. Gray matter volume abnormalities were associated with sustained attention in unmedicated major depression. , 2015, Comprehensive psychiatry.
[12] M. Maes,et al. High predictive value of immune-inflammatory biomarkers for schizophrenia diagnosis and association with treatment resistance , 2015, The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry.
[13] I. Goodyer. Genes, environments and depressions in young people , 2015, Archives of Disease in Childhood.
[14] Alan A. Wilson,et al. Role of translocator protein density, a marker of neuroinflammation, in the brain during major depressive episodes. , 2015, JAMA psychiatry.
[15] C. Hammen,et al. Effects of Chronic Interpersonal Stress Exposure on Depressive Symptoms are Moderated by Genetic Variation at IL6 and IL1β in Youth , 2015, Brain, Behavior, and Immunity.
[16] Kichun Nam,et al. Impact of lingual gyrus volume on antidepressant response and neurocognitive functions in Major Depressive Disorder: a voxel-based morphometry study. , 2014, Journal of affective disorders.
[17] K. Blennow,et al. Higher CSF interleukin-6 and CSF interleukin-8 in current depression in older women. Results from a population-based sample , 2014, Brain, Behavior, and Immunity.
[18] B. Misiak,et al. Interleukin-6: the missing element of the neurocognitive deterioration in schizophrenia? The focus on genetic underpinnings, cognitive impairment and clinical manifestation , 2014, European Archives of Psychiatry and Clinical Neuroscience.
[19] Min Zhao,et al. Reliability and validity of the Chinese version of the Patient Health Questionnaire (PHQ-9) in the general population. , 2014, General hospital psychiatry.
[20] E. Rimm,et al. C-reactive protein, interleukin-6, soluble tumor necrosis factor α receptor 2 and incident clinical depression. , 2014, Journal of affective disorders.
[21] O. Andreassen,et al. The plasma levels of various cytokines are increased during ongoing depression and are reduced to normal levels after recovery , 2014, Psychoneuroendocrinology.
[22] N. Barnes,et al. Cytokine function in medication-naive first episode psychosis: A systematic review and meta-analysis , 2014, Schizophrenia Research.
[23] Y. D. Reijmer,et al. Markers of low-grade inflammation and endothelial dysfunction are related to reduced information processing speed and executive functioning in an older population – the Hoorn Study , 2014, Psychoneuroendocrinology.
[24] J. Roiser,et al. Cognitive impairment in depression: a systematic review and meta-analysis , 2013, Psychological Medicine.
[25] E. Maylor,et al. Intracellular cytokine production and cognition in healthy older adults , 2013, Psychoneuroendocrinology.
[26] M. Gratacós,et al. Serotonin and interleukin-6: The role of genetic polymorphisms in IFN-induced neuropsychiatric symptoms , 2013, Psychoneuroendocrinology.
[27] F. Lotrich,et al. Inflammatory cytokines in depression: Neurobiological mechanisms and therapeutic implications , 2013, Neuroscience.
[28] R. Murray,et al. Serum and gene expression profile of cytokines in first-episode psychosis , 2013, Brain, Behavior, and Immunity.
[29] N. Sattar,et al. Circulating interleukin‐6 concentration and cognitive decline in old age: the PROSPER study , 2013, Journal of internal medicine.
[30] D. Kinney,et al. Depression as an evolutionary strategy for defense against infection , 2013, Brain, Behavior, and Immunity.
[31] N. Arsenijević,et al. Elevated serum level of type-2 cytokine and low IL-17 in first episode psychosis and schizophrenia in relapse. , 2012, Journal of psychiatric research.
[32] R. Lee,et al. A meta-analysis of cognitive deficits in first-episode Major Depressive Disorder. , 2012, Journal of affective disorders.
[33] R. Ho,et al. Interleukin (IL)-6, tumour necrosis factor alpha (TNF-α) and soluble interleukin-2 receptors (sIL-2R) are elevated in patients with major depressive disorder: a meta-analysis and meta-regression. , 2012, Journal of Affective Disorders.
[34] A. Baker,et al. Interleukin-6, C-reactive protein and interleukin-10 after antidepressant treatment in people with depression: a meta-analysis , 2012, Psychological Medicine.
[35] Wu Hong,et al. Blood-Based Gene Expression Profiles Models for Classification of Subsyndromal Symptomatic Depression and Major Depressive Disorder , 2012, PloS one.
[36] B. Sahakian,et al. Neurocognitive impairment in adolescent major depressive disorder: state vs. trait illness markers. , 2011, Journal of affective disorders.
[37] B. Penninx,et al. Depressive symptoms, health behaviors, and subsequent inflammation in patients with coronary heart disease: prospective findings from the heart and soul study. , 2011, The American journal of psychiatry.
[38] L. Hansson,et al. Cytokines and memory across the mature life span of women. , 2011, Scandinavian journal of psychology.
[39] Andrew H. Miller,et al. Immune system to brain signaling: neuropsychopharmacological implications. , 2011, Pharmacology & therapeutics.
[40] Y. Levkovitz,et al. The effect of age on frontal lobe related cognitive functions of unmedicated depressed patients. , 2011, Journal of affective disorders.
[41] C. Jonker,et al. Homocysteine and inflammation: Predictors of cognitive decline in older persons? , 2010, Neurobiology of Aging.
[42] N. Herrmann,et al. A Meta-Analysis of Cytokines in Major Depression , 2010, Biological Psychiatry.
[43] Jen-Chuen Hsieh,et al. Structural and cognitive deficits in remitting and non-remitting recurrent depression: A voxel-based morphometric study , 2010, NeuroImage.
[44] R. Marioni,et al. Association Between Raised Inflammatory Markers and Cognitive Decline in Elderly People With Type 2 Diabetes , 2009, Diabetes.
[45] Klaus P. Ebmeier,et al. A meta-analysis of depression severity and cognitive function. , 2009, Journal of affective disorders.
[46] T. Kamarck,et al. A prospective evaluation of the directionality of the depression–inflammation relationship , 2009, Brain, Behavior, and Immunity.
[47] Qichang Shi,et al. Prevalence, treatment, and associated disability of mental disorders in four provinces in China during 2001–05: an epidemiological survey , 2009, The Lancet.
[48] S. Bandinelli,et al. Interleukin-1 Receptor Antagonist and Incident Depressive Symptoms Over 6 Years in Older Persons: The InCHIANTI Study , 2009, Biological Psychiatry.
[49] Charles L. Raison,et al. Inflammation and Its Discontents: The Role of Cytokines in the Pathophysiology of Major Depression , 2009, Biological Psychiatry.
[50] J. Suls,et al. Associations of Depression With C-Reactive Protein, IL-1, and IL-6: A Meta-Analysis , 2009, Psychosomatic medicine.
[51] Donald L Rowe,et al. Fronto‐temporal alterations within the first 200 ms during an attentional task distinguish major depression, non‐clinical participants with depressed mood and healthy controls: A potential biomarker? , 2009, Human brain mapping.
[52] M. Marmot,et al. Inflammatory markers and cognitive function in middle-aged adults: The Whitehall II study , 2008, Psychoneuroendocrinology.
[53] M G Marmot,et al. Associations of C-reactive protein and interleukin-6 with cognitive symptoms of depression: 12-year follow-up of the Whitehall II study , 2008, Psychological Medicine.
[54] A. Caspi,et al. Elevated inflammation levels in depressed adults with a history of childhood maltreatment. , 2008, Archives of general psychiatry.
[55] R. Stewart,et al. Markers of inflammation and cognitive decline in an African‐Caribbean population , 2007, International journal of geriatric psychiatry.
[56] Derek T. Y. Mann,et al. Perceptual-cognitive expertise in sport: a meta-analysis. , 2007, Journal of sport & exercise psychology.
[57] R. Westendorp,et al. Inflammation and interleukin-1 signaling network contribute to depressive symptoms but not cognitive decline in old age , 2007, Experimental Gerontology.
[58] N. Börger,et al. Sustained Attention in Major Unipolar Depression , 2007, Perceptual and motor skills.
[59] I. Deary,et al. Cognitive Decline and Markers of Inflammation and Hemostasis: The Edinburgh Artery Study , 2007, Journal of the American Geriatrics Society.
[60] J. Flory,et al. Interleukin-6 Covaries Inversely With Cognitive Performance Among Middle-Aged Community Volunteers , 2006, Psychosomatic medicine.
[61] Johannes Pohl,et al. Attention and executive functions in remitted major depression patients. , 2005, Journal of affective disorders.
[62] M. Skolnick,et al. Genome‐wide linkage analyses of extended Utah pedigrees identifies loci that influence recurrent, early‐onset major depression and anxiety disorders , 2005, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.
[63] Kristopher J Preacher,et al. Chronic stress and age-related increases in the proinflammatory cytokine IL-6 , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[64] M. Korzon,et al. Serum interleukin 6 and interleukin 12 levels in children with chronic hepatitis HBV treated with interferon alpha. , 2003, Annals of hepatology.
[65] Richard J. Porter,et al. Neurocognitive impairment in drug-free patients with major depressive disorder , 2003, British Journal of Psychiatry.
[66] C. Nemeroff,et al. Neurobehavioral Effects of Interferon-α in Cancer Patients: Phenomenology and Paroxetine Responsiveness of Symptom Dimensions , 2002, Neuropsychopharmacology.
[67] H. Link,et al. Enzyme-Linked Immunospot Assays Provide a Sensitive Tool for Detection of Cytokine Secretion by Monocytes , 2001, Clinical Diagnostic Laboratory Immunology.
[68] B. Hagerty,et al. Changes in directed attention and short-term memory in depression. , 2000, Journal of psychiatric research.
[69] K. Akiyama. Serum levels of soluble IL-2 receptor α, IL-6 and IL-1 receptor antagonist in schizophrenia before and during neuroleptic administration , 1999, Schizophrenia Research.
[70] N. Rothwell,et al. Cerebral Interleukin-6 is Neuroprotective during Permanent Focal Cerebral Ischemia in the Rat , 1998, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[71] R G Robinson,et al. Cognitive impairment in the euthymic phase of chronic unipolar depression. , 1997, The Journal of nervous and mental disease.
[72] C. Frith,et al. A fronto-parietal network for rapid visual information processing: a PET study of sustained attention and working memory , 1996, Neuropsychologia.
[73] R. Zinkernagel,et al. Impaired immune and acute-phase responses in interleukin-6-deficient mice , 1994, Nature.
[74] B. Rabin,et al. Serum interleukin-6 concentration in schizophrenia: Elevation associated with duration of illness , 1994, Psychiatry Research.
[75] A M Owen,et al. Computerized assessment in neuropsychiatry using CANTAB: discussion paper. , 1992, Journal of the Royal Society of Medicine.
[76] L. Saugstad,et al. In defence of international classification , 1985, Psychological Medicine.
[77] Muriel D. Lezak,et al. The Problem of Assessing Executive Functions , 1982 .
[78] Lucas Wexler. Principles Of Behavioral Neurology , 2016 .
[79] D. F. Drake,et al. A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers. , 2013, JAMA psychiatry.
[80] R. Grassi‐Oliveira,et al. Interleukin-6 and verbal memory in recurrent major depressive disorder. , 2011, Neuro endocrinology letters.
[81] R. Dantzer,et al. From inflammation to sickness and depression: when the immune system subjugates the brain , 2008, Nature Reviews Neuroscience.
[82] R. Sacco,et al. Interleukin-6 is associated with cognitive function: the Northern Manhattan Study. , 2006, Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association.